Pharmacovigilance 2020 - 22nd Pharmacovigilance 2020 (Virtual Conference)

22nd Pharmacovigilance 2020
“Latest developments in pharmacovigilance, drug safety and RMP”
09th - 10th December 2020, Virtual Conference (Time Zone - EST)
Our event will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Get more from the event, with a broader scope bringing the whole communications value chain together. This event will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. Get more from the event, with a broader scope bringing the whole communications value chain together. Please contact KAVITHA on E-mail - kavitha-AT-virtueinsight.co.in or Call - +44-20 3509 3779
DELEGATE REGISTRATION:
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.
EARLY BIRD PRICING
1 Delegate-AT-US$399 (Valid Till 16th November 2020)
3 Delegates-AT-US$1,099 (Valid Till 16th November 2020)
STANDARD PRICING
1 Delegate-AT-US$599 (From 17th November 2020)
3 Delegate-AT-US$1,499 (From 17th November 2020)
Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to kavitha-AT-virtueinsight.co.in or Call - +44-20 3509 3779
KEY SPEAKERS:
• SONGLIN XUE, Executive Vice President and Global Head of Pharmacovigilance, Astellas Pharmaceuticals
• DIANE E. BECK, Vice President & Head of PV Affiliate Relations Global Patient Safety Evaluation, Takeda Pharmaceuticals
• SHARON REID, Director, Risk Management Product Lead, Pfizer
• BRUNO MENDEZ, VP Global Quality Head Pharmacovigilance, Sanofi
• WILLIAM WANG, Executive Director, Clinical Safety Statistics, Merck
• KHAUDEJA BANO, Executive Medical Director, Combination Product Safety Head, Amgen
• SHAUN COMFORT, Principal Scientific Enablement Director, Roche – Genentech
• DEEPA VENKATARAMAN, Senior Director, Patient Safety Operations, Abbvie
• SHEETAL KHEDKAR, Medical Safety Officer- Oncology, Global Medical Safety, Janssen, Pharmaceutical Companies of Johnson and Johnson
• TANJA PETERS, Head Global Patient Safety Neurology & Immunology, Merck KGaA
• AMGAD SHEBL, Director, Global Clinical Safety & PV / Clinical R&D, CSL Behring
• RICKY RUDRARAJU, Sr. Principal Scientist - Global Patient Safety Evaluation, Takeda Oncology
• RAJ BHOGAL, Sr. Director, R&D Audits & Inspections, Jazz Pharmaceuticals
• MARIA ESTRADA, Medical Director, Pharmacovigilance, Deciphera Pharmaceuticals
• SUMIT MUNJAL, Vice President, Global Patient Safety Evaluation, Takeda
• TEODORA DOHERTY, Global Medical Safety (GMS), Medical Safety Officer, Janssen Research & Development
• SANDRINE VALIERE, Global PV Audit/Inspection Readiness Head, Sanofi
• JAYLAXMI NALAWADE, Associate Director - Pharmacovigilance & REMS, Lupin
• TOYIN ADEWOLE, Assistant Director, Drug Safety, Supernus Pharmaceuticals
• HUMAIRA QURESHI, President, Bioclinica
• MIRCEA CIUCA, Global Therapeutic Area Head - Global Clinical Safety & PV, CSL Behring
• DAVID HUTCHINSON, Founder and Owner, Brookwood Gobal
• HEIDE CUNNING, US Pharmacovigilance Officer-Safety Services Operations, Janssen Pharmaceuticals
• KATARINA ILLIC, Senior Clinical Pharmacology Medical Leader, Takeda Pharmaceuticals
• ANKA G. EHRHARD, Director, Clinical Research, CHDI Foundation
• ADEDEJI ADEFUYE, Head, Medical Safety, Rare Diseases & PDT and Head, CoE for Medical Device Safety, Takeda
• OYINKANSOLA ODEBO, Assistant Director, Drug Safety Clinical Research, Supernus Pharmaceuticals
• BEN LOCWIN, Senior VP, Quality, Lumicell
Plus more joining soon
FOCUSES ON:
• Market analysis – Pharmacovigilance in 2022 - future horizons and efficiencies
• Regulations, Legal & Brexit Implications for the pharmacovigilance Industry
• Outsourcing in Pharmacovigilance- Best Practices, Challenges and key consideration
• New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT, Blockchain & Big Data)
• PV Audit & Inspections – Knowing what is to be done
• RWE & RWD
• Documentation (RMPs, PSURs, PADERs, PBRERs)
• Quality, Safety and Signal Detection - Future of 2020
• Medical devices – Increasing safety perspective
• Case studies from various countries on the PV frameworks around the world
• Patient centric approach to help improve patient safety
• The developing regulatory framework in advanced and developing markets – EU, USA & ROW
• Be part of a major networking opportunity
WHO SHOULD ATTEND:
Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing
Get more from the event, with a broader scope bringing the whole communications value chain together.